ResMed Inc (RMD, Financial) is set to release its Q4 2024 earnings on Aug 1, 2024. The consensus estimate for Q4 2024 revenue is $1.22 billion, and the earnings are expected to come in at $2.00 per share. The full year 2024's revenue is expected to be $4.68 billion and the earnings are expected to be $6.94 per share. More detailed estimate data can be found here.
ResMed Inc (RMD, Financial) Estimate Trends
Over the past 90 days, revenue estimates for ResMed Inc (RMD) have increased from $4.68 billion to $4.68 billion for the full year 2024, and from $5.01 billion to $5.02 billion for 2025. Earnings estimates have risen from $6.92 per share to $6.94 per share for the full year 2024, and from $8.18 per share to $8.22 per share for 2025.
ResMed Inc (RMD, Financial) Reported History
In the previous quarter of March 31, 2024, ResMed Inc's (RMD) actual revenue was $1.20 billion, which beat analysts' revenue expectations of $1.17 billion by 2.56%. ResMed Inc's (RMD) actual earnings were $2.04 per share, which beat analysts' earnings expectations of $1.79 per share by 14.03%. After releasing the results, ResMed Inc (RMD) was up by 18.89% in one day.
ResMed Inc (RMD, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 10 analysts, the average target price for ResMed Inc (RMD) is $218.46 with a high estimate of $238 and a low estimate of $180. The average target implies an upside of 1.4% from the current price of $215.44.
Based on GuruFocus estimates, the estimated GF Value for ResMed Inc (RMD, Financial) in one year is $302.28, suggesting an upside of 40.31% from the current price of $215.44.
Based on the consensus recommendation from 15 brokerage firms, ResMed Inc's (RMD, Financial) average brokerage recommendation is currently 2.3, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies a strong buy, and 5 denotes a sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
